Skip to main content

Table 1 The incidence of mammary gland tumors in multiparous mice. The pathology of mammary tumors and premalignant lesions were assessed according to the consensus report from the Annapolis meeting on the mammary pathology of genetically engineered mice [33]. WT, wild type; T16, MMTV-cortactin mice; MP1, MMTV-cyclin D1 mice; T16*MP1, bitransgenic mice; wk, weeks; % MG T = no. of mice with mammary gland tumors per total no. mice; a.s.car = adeno(squamous)carcinoma of the MG; other MG car. = other MG carcinoma (see table 2); Some mice beared more than one MG carcinoma (see table 2). MIN = mammary intraepithelial neoplasia; HAN = hyperplastic alveolar nodules. MIN+HAN = no. of mice bearing MIN and/or HAN.

From: Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice

  No. of mice % MG T a.s.car. MG other MG car. mean age of MG tumor onset (wk) MIN HAN HAN+MIN
WT FVB/N 34 13 (38%) 11 (32%) 5 (15%) 97 21 (62%) 22 (65%) 26 (76%)
T16 (cortactin) 28 6 (21%) 6 (21%) 1 (4%) 100 15 (55%) 19 (68%) 23 (82%)
MP1 (cyclin D1) 15 6 (40%) 4 (27%) 4 (27%) 91 7 (47%) 9 (60%) 13 (87%)
T16 * MP1 23 7 (30%) 6 (26%) 1 (4%) 89 8 (35%) 14 (61%) 15 (65%)